Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| HC HCMHUTCHMED (China) Limited | $12.63+0.6% | $2.20B | 24 assetsPhase 3 | IMG-007 (OX40 Antagonist)Phase 2b · Data readout | |
| HC HCWBHCW Biologics | $2.18+2.8% | $4.0M | 4 assetsPhase 1 |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| HE HEPAHepion Pharmaceuticals | $0.08+0.0% | $6.8M | 2 assetsStage unavailable | No dated catalyst |
| HG HGENHumanigen Inc. | — | — | 7 assetsStage unavailable | No dated catalyst |
| HL HLVXHilleVax | $2.09+0.0% | $104.8M | 2 assetsStage unavailable | No dated catalyst |
| HO HOOKHOOKIPA Pharma Inc. | $1.15+0.9% | $14.2M | 7 assetsStage unavailable | No dated catalyst |
| HO HOWLWerewolf Therapeutics | $0.87+102.6% | $42.5M | 4 assetsPhase 1/2 | WTX-330 (IL-2 INDUKINE™)Phase 1/2 · Data readout |
| HR HRMYHarmony Biosciences Holdings Inc | $38.15+0.2% | $2.22B | 14 assetsPDUFA | BP1.15205Phase 1 · Data readout |
| HR HRTXHeron Therapeutics | $0.32+3.0% | $60.4M | 5 assetsStage unavailable | No dated catalyst |
| HU HUMAHumacyte | $0.64-5.8% | $178.4M | 3 assetsStage unavailable | No dated catalyst |
| IB IBIOiBio Inc. | $1.43-2.7% | $71.0M | 3 assetsPhase 1 | IBIO-600 (Myostatin Antibody)Phase 1 · Data readout |
| IB IBRXImmunityBio | $7.79-0.6% | $8.26B | 15 assetsStage unavailable | No dated catalyst |
| IC ICPTIntercept Pharmaceuticals | $19.00+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| IC ICVXIcosavax | $15.31+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| ID IDYAIDEAYA Biosciences | $39.67+1.4% | $3.83B | 19 assetsPhase 2/3 | Darovasertib (IDE196) + crizotinibPhase 2/3 · Data readout |
| IF IFRXInflaRx N.V. | $2.10+4.0% | $309.5M | 13 assetsPhase 2a | Izicopan (C5aR Inhibitor)Phase 2a · Data readout |
| IG IGMSIGM Biosciences | $1.27+0.0% | $76.6M | 10 assetsStage unavailable | No dated catalyst |
| IK IKNAIkena Oncology | $5.51-1.8% | $718.8M | 4 assetsStage unavailable | No dated catalyst |
| IK IKTInhibikase Therapeutics | $2.39+1.7% | $333.5M | 3 assetsStage unavailable | No dated catalyst |
| IM IMAImageneBio | $5.51-1.8% | $62.7M | 2 assetsPhase 2b | IMG-007 (OX40 Antagonist)Phase 2b · Data readout |
| IM IMABI-Mab | $4.63-0.2% | $533.7M | 14 assetsPhase 2 | Givastomig (TJ-CD4B/ABL111) combo w/ nivolumab + chemoPhase 1b · Data readout |
| IM IMCRImmunocore Holdings | $36.88+1.7% | $1.90B | 13 assetsPhase 3 | KIMMTRAK (Tebentafusp) +/- anti-PD1Phase 3 · Data readout |
| IM IMGNImmunoGen | $31.23+0.0% | $8.72B | 7 assetsStage unavailable | No dated catalyst |
| IM IMMPImmutep | $0.39-1.3% | $56.9M | 9 assetsPhase 2 | Eftilagimod Alpha + PembrolizumabPhase 2 · Data readout |
| IM IMNMImmunome | $28.52+1.6% | $3.24B | 7 assetsPDUFA | IM-1021 (ROR1 ADC)Phase 1 · Data readout |
| IM IMNNImunon | $1.64+3.8% | $9.2M | 2 assetsStage unavailable | No dated catalyst |
| IM IMPLImpel NeuroPharma | — | — | 3 assetsStage unavailable | No dated catalyst |
| IM IMRXImmuneering Corporation | $5.30+1.0% | $342.9M | 8 assetsPhase 3 | Atebimetinib (IMM-1-104) (MEK Inhibitor)Phase 3 · Data readout |
| IM IMTXImmatics | $8.93+4.4% | $1.22B | 13 assetsPhase 3 | ACTengine® IMA203CD8 GEN2 (PRAME) Phase 1 · Data readout |
| IM IMUXImmunic | $16.50+2.5% | $225.1M | 8 assetsPhase 3 | Vidofludimus calcium (IMU-838) Phase 3 · Data readout |
| IM IMVIMV Inc. | — | — | 7 assetsStage unavailable | No dated catalyst |
| IM IMVTImmunovant | $44.37+0.0% | $9.16B | 12 assetsPhase 3 | IMVT-1402Phase 2b · Data readout |
| IN INABIN8bio | $1.28+5.8% | $12.6M | 4 assetsPhase 1 | INB-100Phase 1 · Data readout |
| IN INBXInhibrx Inc. | $103.63+4.5% | $1.53B | 6 assetsPDUFA | INBRX-106 (OX40 agonist) + Keytruda Phase 2 · Data readout |
| IN INCYIncyte Corporation | $127.81+0.5% | $25.91B | 34 assetsPDUFA | Povorcitinib (JAK1) Phase 3 · Data readout |
| IN INKTMiNK Therapeutics | $12.20+5.0% | $62.3M | 4 assetsPhase 2 | AgenT-797 +/- pembrolizumab/nivolumabPhase 2 · Data readout |
| IN INMBINmune Bio | $2.32+7.4% | $64.4M | 5 assetsPhase 1/2 | INKmune™Phase 1/2 · Data readout |
| IN INOInovio Pharmaceuticals | $1.18-2.5% | $122.0M | 13 assetsPDUFA | INO-3107PDUFA · Approval decision |
| IN INSMInsmed Incorporated | $125.77+0.6% | $27.47B | 10 assetsPhase 3 | No dated catalyst |
| IN INTSIntensity Therapeutics | $4.86-0.4% | $15.9M | 3 assetsPhase 1/2 | INT230-6 (Intratumoral Cytotoxic)Phase 1/2 · Data readout |